| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8786183 | Clinical Oncology | 2018 | 7 Pages |
Abstract
Carefully selected ABC patients have been found to tolerate experimental phase I clinical trials without excess toxicity. The aggressive nature of this disease warrants consideration of early referral to a phase I unit. Future work will require comprehensive molecular profiling in an attempt to understand the biology underlying the exceptional responders and to match patients in real-time to targeted therapies.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
R. Sundar, A. Custodio, A. Petruckevich, M. Chénard-Poirier, M. Ameratunga, D. Collins, J. Lim, S.B. Kaye, N. Tunariu, U. Banerji, J. de Bono, J. Lopez,